This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): ACH-806
Description: GS 9132 is a drug that inhibits hepatitis C viral replication through its effect on HCV protease.
Deal Structure: In November 2004, Gilead and Achillion established an agreementgranting Gilead worldwide rights for the research, development andcommercialization of certain Achillion compounds for the treatment ofhepatitis C. GS 9132 is a small molecule inhibitor of hepatitis Cvirus (HCV) replication, which works through a novel mechanism ofaction involving HCV protease. GS 9132 was discovered by Achillion,and the company completed the initial work necessary to move thecompound into clinical development.
Partners: Achillion Pharmaceuticals, Inc.
GS 9132 News
Additional information available to subscribers only: